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Ethnopharmacological relevance: Leaves of Pyrostegia venusta are popularly used to treat vitiligo;
however, none in vivo study showed its ability.
Aim of the study: The overall objective of the present study was to evaluate the antiinﬂammatory and
hyperpigmentant activities of hydroethanolic (HE) extract of leaves from P. venusta in animal models of
vitiligo induced by croton oil and monobenzone.
Materials and methods: The antiinﬂamatory and antioxidative effects of topical and oral administration of
HE extract of P. venusta were evaluated in Swiss mice on edema model induced by croton oil, and further
the N-acetyl-b-D-glucosaminidase (NAG) activity, cell inﬁltration, and cytokine and reactive species
oxygen (ROS) levels. The involvement on mice pigmentation, cell inﬁltration and cytokine levels were
evaluated on vitiligo model induced by monobenzone in C56BL/6 mice.
Results: HE of P. venusta by gavage (300 mg/kg) reduced NAG activity in 32.575% on mouse ear edema
induced by croton oil. Similarly, cell inﬁltration was lower (42.375.9%) when compared to control group,
as well as interleukin-1β (IL-1β), interleukin (IL-6) and tumor necrosis factor-α (TNF-α) levels, in
44.179.7%, 71.9722.2% and to basal levels, respectively. Topical treatment with HE of P. venusta (10%)
diminished cell inﬁltration (67.777.1%) and ROS levels (total reduction). P. venusta either by gavage
(300 mg/Kg) or topically (10%) increased epidermal melanin level (116.5713% and 100716.9%,
respectively), diminished dermal depigmentation (36.076.7% and 38.276.2%, respectively), as well as
tissue TNF-α levels (68.2711.6% and 99.2712.1%, respectively) and cell inﬁltration (basal levels and
94.379.17%, respectively). However, only topical treatment with HE of P. venusta altered melanin speciﬁc
marker in hair follicles.
Conclusions: For the ﬁrst time these data show that topical and oral administrations of P. venusta have
signiﬁcant antiinﬂammatory and hyperpigmentant effects, demonstrating different topical and systemic
effects through two animal models. Together these models are capable to mimic several features founded
in vitiligo, and the results support the ethnopharmacological use of P. venusta.
& 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Vitiligo is a common skin disorder characterized by acquired loss of
constitutional pigmentation manifesting as white macules caused by
damage of functional epidermal melanocytes. This disease usually
begins in childhood or young adulthood without distinction of
ethnicity or gender (Halder and Chappell, 2009). There are several
hypotheses regarding the etiology of vitiligo, however, none can
explain its onset and progression (Roy, 2007). A complex interplay of
biochemical, genetic, environmental and immunological factors occurs
in the evolution of generalized vitiligo (Glassman, 2011).
Nowadays, many options of treatment are available to vitiligo
patients. The alternatives can be divided into groups: topical
corticosteroids, immunomodulators and calcipotriol; pseudocata-
lase; systemic therapies; vitamin D analogs; phototherapy; excimer
laser; depigmentation and surgical modalities. Though most of
them are able to restore the pigmentation of the skin, they have
some disadvantages where many patients do not respond to the
therapy or demonstrate side effects that impair the patient adher-
ence to the treatment (Halder and Chappell, 2009). Thus, rising
research works have focused on the understanding of the disease
and, consequently, in the search for new therapeutic targets.
Pyrostegia venusta (P. venusta) (Ker-Gawl) Miers (family, Bigno-
niaceae), popularly known as “cipó-de-são-joão” is widely dis-
tributed in southern Brazil. Native brazilians use all parts of the
plant as medicine, including ﬂowers, leaves, roots and stem
(Scalon et al., 2008). Aerial parts are mainly used in decoction or
infusion as a general tonic, to treat diarrhea and white patches
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(vitiligo) (Ferreira et al., 2000; Scalon et al., 2008; Veloso et al.,
2010). Several researchers have proved pharmacological activities
of P. venusta as antioxidant, antiinﬂammatory, antinociceptive,
wound healing, antimicrobial (Roy et al., 2012) and melanogenic
properties (Moreira et al., 2012; Roy et al., 2012; Veloso et al.
2012). Previously, we have shown that hydroethanolic extract (HE)
of ﬂowers and leaves of P. venusta were capable of enhancing
melanin content on B16F10 murine cell line at low concentrations
(Moreira et al., 2012).
Considering the need to seek new therapies, the ethnopharma-
cological use of P. venusta and the previous study associated with
the increase of melanin content in vitro, the aim of this study was
to evaluate the activity of HE from leaves of P. venusta in animal
models of vitiligo.
2. Material and methods
2.1. Drugs and reagents
The following reagents were used: croton oil, 20,70-Dichloroﬂuor-
escin diacetate (DCFH-DA), N-acetyl-beta-D-glucosaminidase (NAG),
monobenzone [4-(Benzyloxy) phenol or hydroquinone monobenzyl
ether], melanin synthetic, tacrolimus (all from Sigma Chemical Co., St
Louis, USA) and mice ELISA kit (Ready-Set-gos 88-7013, 88-7064 and
88-7324, eBioscience, San Diego, USA).
2.2. Botanical material and extract obtention
Leaves of P. venusta were collected in May 2013 in the city of
Colombo (coordinates: S 25119´31´´), Paraná, Brazil. The specie was
identiﬁed by Osmar dos Santos Ribas from Municipal Botanic
Museum of Curitiba (MBM). A voucher specimen was deposited
at MBM in Curitiba, Paraná, Brazil. Leaves of P. venusta (100 g) were
air dried (40 1C, forced ventilation), powdered and extracted with
ethanol:water (70:30, v/v) by turbolysis (Ultra Turrax Biotrona BA
80, Kinematica AG) at room temperature for 2 h. HE was ﬁltered
through a ﬁlter paper (Adventec no. 1) followed by solvent reduc-
tion to 1/6 of the initial volume under reduced pressure, lyophilized
and kept at 20 1C. Before pharmacological assays, the lyophilized
HE was dissolved in water or non-ionic cream to produce different
pharmaceutical forms.
2.3. Animals
Experiments were performed on Swiss (female) and C56BL/6
(female and male) mice, weighing 25–35 g. All animals were
housed at 2272 1C under a 12 h light/12 h dark cycle, with access
to food and water ad libitum. The animals were allowed to adapt
to the laboratory for at least 48 h before testing. Swiss mice were
obtained from Universidade Federal do Paraná (UFPR, Curitiba,
Brazil). C56BL/6 mice were obtained from Universidade Federal do
Paraná (UFPR, Curitiba, Brazil) and Universidade Federal de Santa
Catarina (UFSC, Florianópolis, Brazil). Experiments were performed
after approval by the Institutional Ethics of Universidade Federal do
Paraná (Protocol number 738, 2013) and were carried out in accor-
dance with the current guidelines for the care laboratory animals.
2.4. Mouse ear edema induced by multiple applications of croton oil
Cutaneous inﬂammation was induced in Swiss mice by appli-
cation of 0.4 mg/ear of croton oil dissolved in 20 mL of acetone on
alternated days for 9 days (Stanley et al., 1991). HE of P. venusta and
tacrolimus 0.1% (reference drug), were administered from the ﬁfth
day of the trial and applied by oral administration (gavage,
300 mg/Kg) or topically (10% in non-ionic cream) the last four
days twice a day. On the ninth day, animals were euthanized and
6 mm circles of ear tissue were collected and submitted to
assessment of N-acetyl-b-D-glucosaminidase (NAG) activity, histo-
logical analysis (Hematoxylin–eosin staining), measurement of
interleukin-6 (IL-6), interleukin-1β (IL-1β), tumoral necrosis factor
(TNF-α) and reactive oxygen species (ROS) levels.
2.5. Vitiligo model induced by repeated application of monobenzone
Experiments were conducted according to Zhu et al. (2013),
with slight modiﬁcations. Brieﬂy, C57BL/6 mice at 4 weeks of age
were divided into six groups, 4–7 mice in each group. Animals had
the dorsal region shaved, approximately 24 h before. Monoben-
zone 40% was freshly prepared in non-ionic cream and daily
applied (50 mL, for 50 days) to the dorsal region (22 cm2) on
the same site near the tail. Creams were massaged until comple-
tely absorption using a spatula. In a different dorsal region (near
the neck, 22 cm2), tacrolimus (0.1%), or HE of P. venusta 10%
(daily, twice a day) was applied and massaged until completely
absorption. Another group of animals receiving monobenzone was
treated by gavage with HE of P. venusta (300 mg/kg, daily, twice a
day). All treatments were carried out during 65 days. After,
animals were euthanized and 6 mm circles of ear tissue were
collected. All tail and back skin were removed. Some samples were
stored at 80 1C for further tests. Same dorsal skin samples were
collected and placed in 10% neutral buffered formalin to histolo-
gical analysis. Samples also were used to evaluate depigmentation,
epidermal melanin levels, measurement of TNF-α level and histo-
logical analyses (Hematoxylin–eosin and Fontana-Masson staining).
2.6. N-acetyl-b-D-glucosaminidase (NAG) activity
The methodology of Rauh et al. (2011) was used to assess
enzymatic activity. Each sample (6 mm circles of tissue) was added
to 0.75 mL of 80 mM phosphate buffer solution (PBS) pH 5.4 con-
taining 0.5% of hexadecyltrimethyl-ammoniumbromide (HTAB),
and was homogenized (45 s at 0 1C) in a motor-driven homogeni-
zer. The homogenate was decanted into microtubes and added to
0.75 mL of buffer, as previously described. The samples (1.5 mL)
were placed in microfuge tubes and centrifuged at 11,200 g at
4 1C for 20 min. NAG activity was reached with triplicates of 25 μL
of supernatant placed on 96-well plates, followed by the addition
of 100 μL of 50 mM citrate buffer, pH 4.5. The reaction was
initiated by the addition of 25 μL of 2.24 mM NAG. The plate was
incubated at 37 1C for 1 h and the reaction was stopped by the
addition of 30 μL of 200 nM glycine buffer, pH 10.4. The enzymatic
activity was determined colorimetrically using a plate reader
(EL808; BioTech Instruments, INC) set to measure absorbance at
405 nm. The results were expressed as optical density (mOD)/
tissue sample.
2.7. Histological assessment of skin tissue
Ear and back samples were ﬁxed in 10% neutral buffered
formalin. Tissues were subsequently embedded in parafﬁn, sec-
tioned to 5 mm and stained with hematoxylin–eosin or Fontana-
Masson. To evaluate number of stain nuclei ﬁeld, histological
sections stained with hematoxylin–eosin of ear and back were
photographed in increments of 200 and the photographs were
analyzed with the ImageJ software version 1.47 (National Institute
of Health, USA). Analyses were performed by counting cells per
ﬁeld. Ten ﬁelds from three distinct histological sections of each
group were analyzed.
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2.8. Fontana-Masson staining
Histological sections of back skin were deparafﬁnized and
hydrated in successive baths of xylene and alcohol and stained
with Fontana-Masson. Samples were soaked in the solution of
silver nitrate for 1 h in an oven at 56 1C and then washed with
distilled water. Next, slices were subjected to gold chloride
solution for 10 min and then washed in distilled water. Samples
were then reduced in 5% sodium thiosulfate solution for 5 min,
washed and dipped in nuclear fast red solution for 5 min. Finally
they were rinsed in distilled water, dehydrated, and mounted with
Canada balsam followed by coverslip.
2.9. Measurement of IL-1β, IL-6 and TNF-α levels
Amounts of IL-1β, IL-6 and TNF-α in the ear and dorsal tissue
homogenates were quantiﬁed using ELISA kit (eBioscience, San
Diego, USA) according to the manufacturer instructions. Levels of
these cytokines in each supernatant were normalized to total
protein content, which was determined using Bradford protein
assay (Bio-Rad Laboratories, Hercules, CA, USA).
2.10. Evaluation of intracellular reactive oxygen species (ROS)
Evaluation of intracellular ROS was conducted accordingly to
Hempel et al. (1999) with slight modiﬁcations. Brieﬂy, tissue samples
were homogenized in 80 mM of PBS (pH 7.2) for 45 s at 0 1C.
Homogenates were incubated with 2 mM DCFH-DA for 40 min
(37 1C). Conversion of DCFH-DA to ﬂuorescent DCFH was assessed
using a plate reader (EL808; BioTech Instruments, INC) 485 nm
(excitation) and 530 nm (emission). Vitamin E (0.3 mg/ear) was used
as positive control. The results were expressed as ﬂuorescent unit.
2.11. Depigmentation evaluation
The extent of depigmentation in the treated groups was analyzed
by objective observation by two blinded observers. Each exposure
location (monobenzone application site) and the extent of depigmen-
tation (monobenzone non-application site) were examined and
estimated as a depigmentation effect, which was the result of total
depigmented sites observed in each animal/group.
2.12. Determination of epidermal melanin levels
Tail samples were submitted to melanin assessment. Pre-
viously, epidermis was separated of dermis with 20 mM ethyle-
nediamine tetraacetic acid (EDTA) solution (37 1C, overnight). It
was added 0.5 mL of RIPA buffer (1 M Tris buffer, 4 M sodium
chloride, 20 mM EDTA, 1% triton, 0.1% sodium dodecyl sulfate, 0.5%
deoxycolate sodium and H2O Milli-Q), homogenized and centri-
fuged (12,000 g, 20 min, 4 1C). Supernatants were separated and
20% dimethyl sulfoxide (DMSO) in 1 N sodium hydroxide (NaOH)
solution was added to pellet and kept boiling until the pellets
dissolved. The melanin levels were determined colorimetrically
using a plate reader (EL808; BioTech Instruments, INC) set to
measure absorbance at 470 nm. Curve of synthetic melanin was
used as reference. Concentrations were normalized to total protein
content in supernatants, which was determined using Bradford
protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Results
were expressed as melanin concentration (mg/mL)/mg epidermis.
2.13. Determination of dermal pigmentation
Immediately after epidermis removal, pictures of the dermis
were taken with Canon Camera (T3i model, EF-S lens, 18–55 mm).
Same area was analyzed for each animal and changes to shades of
gray (0–255 scale) and histograms were generated (Photoshop
software, version 9). Scale mean by group was plotted in a graphic.
Results were expressed as dermis pigmentation.
2.14. Statistical analysis
The results were expressed as mean7S.E.M. Data were eval-
uated by one-way analysis of variance (ANOVA) followed by the
Newman–Keuls post-hoc test. Po0.05 was considered as indica-
tive of signiﬁcance. The values were obtained using the Statistical
software GraphPad Prism version 5.00, San Diego California, USA.
3. Results
3.1. Effects of P. venusta on enzymatic activity
Topical application of croton oil promoted an increase in the
tissue NAG activity, which is a marker of mononuclear leukocytes,
indicating an inﬂammatory reaction. P. venusta given by gavage
(Fig. 1) reduced (32.575%; Po0.01) the increase in the NAG
activity.
3.2. Effect of P. venusta on cell inﬁltrate on croton oil model
Representative pictures are shown in Figs. 2 and 3. Histological
preparations of ears tissue showed that repeated applications of
croton oil plus vehicle (Figs. 2 and 3B) caused an intense cell
inﬁltration, when compared to naïve (Figs. 2 and 3A), P. venusta
preparations, topical and oral (Figs. 2 and 3C), and tacrolimus
(Figs. 2 and 3D). Also, repeated topical treatment with P. venusta
(10%) was able to reduce this inﬂammatory parameter in
67.777.1% (Po0.001), and with tacrolimus (0.1%) in 76.578.9%
(Po0.001), as shown in Fig. 2E. Similar results are observed in
Fig. 3E, in which P. venusta administrated by gavage (300 mg/kg)
reduced cell inﬁltration in 42.375.9% (Po0.001), as well as
tacrolimus that reduced in 73.874% (Po0.001).
3.3. Levels of tissue cytokines on croton oil model
Levels of cytokines in the skin samples were higher in ears
submitted to croton oil application when compared with naïve group.
Fig. 1. Effects of Pyrostegia venusta on enzymatic activity induced by multiple
application of croton oil. Croton oil (0.4 mg/ear) was applied once on alternate days
for nine days and hydroethanolic extract (HE) of P. venusta 300 mg/kg was topically
applied after the ﬁfth day for four days, twice a day. NAG activity was measured in
supernatants of homogenates from croton oil treated ears. Tacrolimus (0.1%) was
used as reference drug. Each bar represents the mean7SEM for 5–7 animals. The
graphic symbols denote the signiﬁcance level when compared with control groups.
###Po0.001 (compared to naive group); nnPo0.01 (compared to vehicle group).
Naive (N): without treatment; Vehicle (V): non-ionic cream; Tacrolimus: Tacro.
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In Fig. 4A–C presented cytokines levels after treatment with P. venusta
300mg/kg, which changed the levels of all three analyzed cytokines.
IL-1β (Fig. 4A) was inhibited in 44.179.7% (Po0.01); IL-6 (Fig. 4B) in
71.9722.2% (Po0.05) and TNF-α (Fig. 4C) completely, equal to basal
levels. Also, tacrolimus reduced the cytokines levels showing inhibi-
tion of 52.9712.1% (Po0.01) for IL-1β, 86.4724.2% (Po0.05) for IL-
6, and complete reduction of TNF-α.
3.4. Evaluation of reactive oxygen species (ROS) on croton oil model
Applications of P. venusta 10% cream were able to diminish the
enhancement of intracellular ROS levels caused by croton oil (Fig. 5),
with a ﬁnal amount equal to basal values (when compared to naïve).
3.5. Evaluation of the effect of P. venusta on depigmentation induced
by monobenzone (vitiligo model)
After topical application of monobenzone cream, small white
patches appeared in the drug-exposed area and gradually expanded
to surrounding areas (Fig. 6A). Distant white patches (depigmentation
on the non-exposed sites) were gradually appearing on the eyelashes
(Fig. 6B), abdomen (Fig. 6C), tail (Fig. 6D) and others sites on the back.
On 65th day, depigmentation degrees were established for all treat-
ments groups. All animals of control group (C) presented depigmenta-
tion on monobenzone application site (100% of animals tested). P.
venusta treatment by gavage (300mg/kg) and topical administration
(10%) presented 50% and 20% of animals with depigmentation,
respectively. The group receiving the reference drug shows 85% of
Fig. 2. Effect of topical Pyrostegia venusta on cell inﬁltrate on croton oil model. Representative pictures of histological sections from the ears of mice stained with
hematoxylin–eosin (200 , scale 100 mm) 9 days after multiple croton oil application. (A) Naïve, (B) Croton oil, (C) topic treatment with non-ionic cream incorporated with
10% of hydroethanolic extract (HE) of P. venusta and (D) tacrolimus 0.1% (used as reference drug). (E) Measurement of stained nucleus for analysis of cellular inﬁltrate. Each
bar represents the mean7SEM for 5 animals. The graphic symbols denote the signiﬁcance level when compared with control groups. ###Po0.001 (compared to naive
group); nnnPo0.001 (compared to vehicle group). Naïve (N): without treatment; vehicle (V): non-ionic cream.
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Fig. 3. Effect of oral treatment with Pyrostegia venusta on cell inﬁltrate on croton oil model. (A) Representative pictures of histological sections from the ears of mice stained
with hematoxylin–eosin (200 , scale 100 mm) 9 days after multiple croton oil application. (A) Naïve, (B) Croton oil, (C) Oral treatment with 300 mg/kg of hydroethanolic
extract (HE) of P. venusta and (D) tacrolimus 0.1% (used as reference drug). (E) Measurement of stained nucleus for analysis of cellular inﬁltrate. Each bar represents the
mean7SEM for 5 animals. The graphic symbols denote the signiﬁcance level when compared with control groups. ###Po0.001 (compared to naive group); nnnPo0.001
(compared to vehicle group). Naïve (N): without treatment; vehicle (V): water.
Fig. 4. Levels of cytokines in supernatants of tissue homogenates from croton oil model. Measurements of IL-1β (A), IL-6 (B) and TNF-α (C) levels were performed with
commercial ELISA kit in supernatants of homogenates from P. venusta 300 mg/kg (A, B, C) treatment on croton oil model. Tacrolimus (0.1%) was used as reference drug. Each
bar represents the mean7SEM for 5–7 animals. The graphic symbols denote the signiﬁcance level when compared with control groups. #Po0.05, ###Po0.001 (compared to
naïve group); nPo0.05, nnPo0.01 (compared to vehicle group). Naïve (N): without treatment; vehicle (V): water (A, B, C); tacrolimus: tacro.
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animals with depigmentation on the application site. The percentage
value refers only about the presence or not of depigmentation in the
animal. Also, the depigmentation by monobenzone in non-application
sites was evaluated and in the control group (monobenzone 40%) all
the tested animals presented depigmentation. Meanwhile, only 33%
and 40% of animals treated with P. venusta by gavage and topically,
respectively, showed depigmentation.
3.6. Effects on epidermal melanin levels after P. venusta treatments
on vitiligo model
Melanin concentration was evaluated on samples from tail skin
and all the groups show differences (Fig. 7A and B). Control group
exhibited 44.3711.6% (Po0.01) less melanin when compared to
naïve group. This decrease in melanin content was not observe in
P. venusta topically and tacrolimus (0.1%) treated groups, which
showed an enhancement of epidermal melanin of 100716.9%
(Po0.01) and 116.5713% (Po0.01), respectively, compared to
control group. These values represented 2.0-folds and 2.2-folds
(Fig. 7A) more melanin than control. Similar result was observed
when P. venusta was given by gavage. Control group presented
33.279.1% (Po0.05) less melanin compared to naïve group, while
P. venusta 300 mg/kg and tacrolimus (0.1%) showed 46.279.8
(Po0.05) and 74.0710.4% (Po0.01), respectively, more melanin
in comparison to control. These data represent 1.5-folds and 1.7-
folds when compared to control group (Fig. 7B).
3.7. Effects on dermal pigmentation after P. venusta treatments on
vitiligo model
After euthanasia, the dermis and the epidermis were separated
from the skin of the back collected. Dermis pictures were taken from
monobenzone application site of all animal groups. Representative
histograms of each group were shown in Fig. 8A (naïve), 8B (vehicle
water), 8 C (vehicle cream), 8D (P. venusta 10%), 8E (P. venusta 300 mg/
kg) and 8 F (tacrolimus). Black: left side; white: right side. As shown
in Fig. 8G, topical P. venusta was 38.276.2% (Po0.05) different from
control, meaning that there was a higher frequency next to black side,
and tacrolimus value was 45.276.6% (Po0.05). Similarly, P. venusta
(300 mg/kg) and tacrolimus showed signiﬁcant differences group of
36.076.7% (Po0.05) and 38.777.4% (Po0.05), respectively, when
compared to the control (Fig. 8H).
3.8. Tissue levels of TNF-α on vitiligo model
Levels of tissue TNF-αwere different between naïve and control
group. Topical P. venusta (Fig. 9A) was capable to diminish TNF-α
levels in 99.2712.1% (Po0.001), while oral P. venusta 300 mg/kg
(Fig. 9B) diminished in 68.2711.6% (Po0.001). Tacrolimus
showed an overall reduction (100%), reaching basal levels.
3.9. Histological evaluation of melanin trough Fontana-Masson
staining the skin from vitiligo model
Back skin samples were stained with Fontana-Masson and
melanin was marked in brown color inside the hair follicles. As
observed in representative ﬁgures, monobenzone control group
Fig. 5. Evaluation of reactive oxygen species (ROS) in supernatants of tissue
homogenates from croton oil model. Measurements of ROS production were
performed after P. venusta 10% treatment on croton oil model from homogenized
tissues. Ears were incubated with DCFH-DA (2 mM) and results were expressed as
ﬂuorescent unit. Vitamin E (0.3 mg/ear) was used as reference drug. Each bar
represents the mean7SEM for 5–7 animals. The graphic symbols denote the
signiﬁcance level when compared with control groups. #Po0.05 (compared to
naïve group); nnPo0.01 (compared to vehicle group). Naïve (N): without treat-
ment; vehicle (V): non-ionic cream.
Fig. 6. Evaluation of depigmentation effect induced by monobenzone model in mice. During 50 days C57BL/6 mice received monobenzone cream (40%) on speciﬁc site of its
back and different treatments were giving topically or given by gavage, once a day, during 65 days. On 65th day, depigmentation was evaluated on (A) the monobenzone-
exposed site (red circle) and (B, C, D) non-exposed site (red arrow and square). Mice were divided into: control (water or non-ionic cream), P. venusta (10%), P. venusta
(300 mg/kg) and tacrolimus (0.1%). Naïve (N) group: mice with no treatment. Evaluation was conducted by two blinded experimenters. N¼4–7 animals. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Fig. 10B) presented low melanin levels compared to naïve group
(Fig. 10A). P. venusta topically (Fig. 10C) and tacrolimus (Fig. 10E)
groups showed higher amounts of melanin pigment. On the other
hand, P. venusta given by gavage (Fig. 10C) was not able to restore the
pigmentation.
3.10. Effect of P. venusta on cell inﬁltrate on vitiligo model through
histological analysis
Back skin samples were stained with Hematoxylin–eosin and cell
inﬁltrate was evaluated. Representative pictures are shown in Fig. 11A
Fig. 7. Effects on epidermal melanin levels after Pyrostegia venusta treatments on monobenzone model. After 65 days C57BL/6 mice were euthanized, tails (A, B) epidermis
was separated to evaluate the melanin content. Effects of (A) P. venusta (10%) and (B) P. venusta (300 mg/kg) were assessed. Naïve (N) group: mice with no treatment.
Tacrolimus: Tacro (0.1%) was used as reference drug. Each bar represents the mean7SEM for 4–7 animals. The graphic symbols denote the signiﬁcance level when compared
to naïve group (#Po0.5) and control group (nPo0.05, nnPo0.01).
Fig. 8. Effects on dermal depigmentation after Pyrostegia venusta treatments on monobenzone model. After 65 days C57BL/6 mice were euthanized. Dermis from back
treated with P. venusta 10% and P. venusta 300 mg/kg were separated and pictures were taken, changed to gray scale and histograms were generated: (A) Naïve (N), (B and C)
control (water or non-ionic cream), (D) P. venusta (10%), (E) P. venusta (300 mg/kg) and (F) tacrolimus (0.1%). Naïve (N) group: mice with no treatment. Tacrolimus was used
as reference drug. Graphics of mean of each group were generated for (G) P. venusta 10% and (H) P. venusta 300 mg/kg. Each bar represents the mean7SEM for 4–7 animals.
The graphic symbols denote the signiﬁcance level when compared to control group (nPo0.05). Gray scale: 0 (black)–255 (white).
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(Naïve), Fig. 11B (Control: monobenzone), Fig. 11C (P. venusta 10%),
Fig. 11D (P. venusta, 300 mg/kg) and Fig. 11E (tacrolimus). Both P.
venusta treatments were capable to reduce in 94.3%79.17% (topical;
Po0.001) and in 100% (oral; Po0.001) (Fig. 11F and G) reaching basal
levels of cell inﬁltrate. Similar results were observed in the tacrolimus
group, where the treatment totally inhibited the cellular inﬁltration.
4. Discussion
Although essentially asymptomatic, the psychosocial impact of vitiligo
should be considered, and the affected people are often searching for
effective therapy (Linthorst et al., 2009). Current vitiligo therapy
demonstrates variable response rates. Often it is necessary to use
rotational therapy to diminish side effects and to achieve better
repigmentation response (Halder and Chappell, 2009).
During the past decades, thousands of plant extracts were
screened and identiﬁed as potential skin-lightening agents (Zhu
and Gao, 2008). However, there are few studies showing plant
extracts with hyperpigmentant activity. P. venusta is popularly
used to treat patches and vitiligo, however, no study presents data
that support its ability. In a previous in vitro study it was revealed
that HE extract of P. venusta leaves was able to enhance melanin
production in B16F10 cell line without affecting cell viability
(Moreira et al., 2012). Yet, there are no studies that veriﬁed their
action in animal models.
Fig. 9. Levels of TNF-α in supernatants of tissue homogenates from monobenzone model. Measurements of ears TNF-α (A, B) levels were performed with commercial ELISA
kit in supernatants of homogenates from P. venusta 10% (A) and 300 mg/kg (B) treatments on monobenzone model. Tacrolimus (0.1%) was used as reference drug. Each bar
represents the mean7SEM for 4–7 animals. The graphic symbols denote the signiﬁcance level when compared to naïve group (###Po0.001) and control group
(nnnPo0.001). Naïve (N): without treatment; vehicle (V): non-ionic cream (A) or water (B); tacrolimus: tacro.
Fig. 10. Histological evaluation of melanin trough Fontana-Masson staining. Representative pictures of melanin contents between naïve (A), control (B), P. venusta 10% (C), P.
venusta 300 mg/kg (D) and tacrolimus (E) groups were evaluated on 65th day. Representative pictures of histological sections from back stained with Fontana-Masson
indicated that melanin levels were evidently elevated on P. venusta 10% and on reference drug. (200 , scale 200 mm). Naïve: without treatment; control: monobenzone 40%.
(For interpretation of the references to color in this ﬁgure, the reader is referred to the web version of this article.)
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Monobenzone-induced vitiligo model has been explained by the
structural homology of monobenzone with tyrosine, the natural
substrate of melanogenesis. Monobenzone is then converted into a
highly reactive quinone by tyrosinase, and the subproducts react with
surrounding enzymatic compounds within the conﬁnes of the mela-
nosomal organelle. This reaction induces modiﬁcations in the melano-
somal enzymes and alters their recognition by Tcells, which can lead to
the break of the immune tolerance (Hariharan et al., 2011). Besides,
monobenzone is capable to synergize autoimmune and reactive
oxygen species mediating melanocyte destruction and vitiligo-like
depigmentation (van den Boorn et al., 2011). In the animal model of
topical application of monobenzone there is a systemic immune
response to autologous melanocytes and similar vitiligo histological
features (Zhu et al., 2013).
Croton oil is a phlogistic agent that contains phorbol esters, mainly
12-O-tetradecanoylphorbol-13-acetate (TPA), which, when topically
applied, promotes manifestation of several inﬂammatory parameters
similar to that observed in some skin disorders. Additionally, the
signaling pathway dependent on protein kinase C (PKC) activates
phospholipase D, inducing melanogenesis suppression (Conricode
et al., 1992). Under physiological conditions, TPA also can inhibit
transcription mediated by PKC and enhanced tyrosinase degradation
mediated by phospholipase A2 (PLA2) (Kageyama et al., 2004).
Furthermore, in the presence of TPA the number of dendrites of
melanocytes is decreased in vitro; consequently causes a decrease in
the ability to transfer melanosomes from melanocytes to the neigh-
boring keratinocytes (Nakazawa et al., 1993).
Over the years, many studies have shown that there is a
relationship between inﬂammation and vitiligo. It seems to be
observed the presence of a low intensity inﬂammatory inﬁltrate of
mononuclear cells comprised between the upper layer of the dermis
and epidermis–dermis interface (Taieb and Picardo, 2009). The silent
Fig. 11. Histological evaluation of cell inﬁltrate trough Hematoxylin–eosin staining. Number of cell inﬁltrate between naive (A), control (B), P. venusta 10% (C), P. venusta
300 mg/kg (D) and tacrolimus (E) groups were evaluated on 65th day. Representative pictures of histological sections from back stained with HE indicated that cell number
was reduced on P. venusta 10% and tacrolimus groups (300 , scale 200 mm). P. venusta 10% (Fig. 11F) and 300 mg/kg (Fig. 11G). Naïve (N): without treatment; control:
monobenzone 40%.
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microinﬂammatory reaction may be the responsible for triggering
local warnings of the innate immune system and precedes adaptive
immune responses directed to melanocytes, like release of many
substances, including pro-inﬂammatory mediators and proteolytic
enzymes, including ROS (Arnhold, 2004; Bradley et al., 1982). These
mediators are responsible for sustaining the inﬂammatory process,
and activate other cell types, such as T lymphocytes (Terui and
Tagami, 2000). P. venusta was capable to reverse many features
induced by croton oil model, like cell inﬁltrate, ROS production and
cytokine release. ROS are products of the melanogenesis process in
melanocytes and are controlled by several antioxidant enzymes.
Considering the role of oxidative stress on melanogenesis and on the
immune system, it is hypothesized that the biochemical pathway in
the biosynthesis of melanin defects can be partially responsible by
ROS formation (Casp et al., 2002).
Monobenzone is also capable of upregulating genes that encode
cytokines and chemokines involved in immune responses, like IL-6
and interleukin-8 (IL-8). Then, monobenzone not only affect melano-
cyte viability, but may also contribute to inﬂammation/autoimmune-
mediated progression of vitiligo-like model (Toosi et al., 2012). It is
known that there is an increase in the levels of IL-6 and TNF-α in the
skin of patients with vitiligo. Also increased levels of IL-1, IL-6 and IL-8
can be found peripherally (Glassman, 2011). In addition, release of
inﬂammatory cytokines, especially IL-1, IL-6 and TNF-α after a skin
trauma (Koebner phenomenon), can lead to recruitment of T cells in
the skin and exposing new antigens expressed in melanocytes
(Miniati et al., 2014).
In both applied models, there was an enhancement of cytokines
levels. Croton oil promoted release of Il-1β, IL-6 and TNF-α while
monobenzone induced just TNF-α release. Therefore, P. venusta
could avoid this enhancement and probably prevent recruitment
of T cells in the skin, IL-8 upregulation, apoptosis of keratinocytes,
and melanocytes; contributing to preventing the progression of
vitiligo. Our results showed that monobenzone enhanced TNF-α
level and both evaluated P. venusta preparations protected from this
effect.
It is known that TNF-α up regulates expression of IL-8 receptor
in normal melanocytes and in early stages when the melanocytes
are still present in the epidermis, TNF-α released by various cell
types could stimulate the expression of IL-8 by melanocytes in the
skin (Miniati et al., 2014; Norgauer et al., 2003). Furthermore, an
imbalance of cytokines derived from keratinocytes as IL-6, IL-1 and
TNF-α on lesional skin has been demonstrated, which may impair
the normal functions of melanocyte (Birol et al., 2006; Moretti
et al., 2002) and can initiate apoptosis of both melanocytes and
keratinocytes (Glassman, 2011). TNF-α levels may be altered by
increase of intracellular H2O2 and other ROS (Laddha et al., 2013).
Oxidative stress is considered one of the possible pathogenic
events in the loss of melanocytes (Schallreuter, 1999). Several
sources have documented the production or accumulation of
epidermal H2O2 in vitiligo (Laddha et al., 2013). Additionally,
increased ROS levels in melanocytes may cause defective apopto-
sis, resulting in the release of aberrant proteins, which may serve
as autoantigens, leading to autoimmunity (Kuhtreiber et al., 2003).
In the croton oil model, topically applied non-ionic creamwith 10%
of P. venusta diminished ROS production, contributing to the
reestablishment of immune system.
The melanogenesis of hair follicles in C57BL/6J mice has been
recognized as a useful model for researching pigmentation in vivo
(Ishikawa et al., 2007; Park et al., 2004). It is important to note that
in the mouse dorsal skin, melanocytes are localized exclusively in
the hair follicles, in contrast to humans (Wolnicka-Glubisz et al.,
2013). Topical P. venusta treatment, as well as tacrolimus, showed
noticeably enhancement of melanin inside of hair follicles. These
results complement previously data regarding the ability of
P. venusta to act in the amount of melanin.
5. Conclusion
In summary, we investigated the possible effects of P. venusta on
two in vivo models, which mimic some features of pathogenesis of
vitiligo. Since the treatment was able to act in different parameters
related to the etiopathogenesis of vitiligo, decreasing cellular inﬁltra-
tion, cytokine levels, and oxidative stress, besides increasing melanin
content and pigmentation, HE of P. venusta leaves seems to be a
potential tool for treatment of this disease. Thus, these results conﬁrm
the efﬁcacy of the popular usage of P. venusta to treat vitiligo and
white patches.
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